Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.38 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4449939 | 1.00 | MMP12 (0.47) | MMP12MMP13KDM4EHSD17B10NAPRT | |
| SCHEMBL354141 | 0.82 | CYP3A4 (0.38) | MMP12MMP13KDM4EHSD17B10GRM8 | |
| SCHEMBL5355666 | 0.82 | L3MBTL1 (0.46) | MMP12MMP13KDM4EHSD17B10NAPRT | |
| SCHEMBL904490 | 0.80 | GABBR2 (0.55) | KDM4ECYP2D6CYP2C19GABBR2GABBR1 | |
| SCHEMBL904476 | 0.80 | GABBR2 (0.55) | KDM4ECYP2D6CYP2C19GABBR2GABBR1 | |
| SCHEMBL186610 | 0.80 | GABBR2 (0.55) | KDM4ECYP2D6CYP2C19GABBR2GABBR1 | |
| SCHEMBL6495705 | 0.80 | BCHE (0.44) | MMP12MMP13KDM4EHSD17B10NAPRT | |
| Hydrochloric Acid SCHEMBL1373206 | 0.78 | GABBR2 (0.53) | KDM4ECYP2D6CYP2C19GABBR2GABBR1 | |
| Hydrochloric Acid SCHEMBL1374836 | 0.78 | GABBR2 (0.53) | KDM4ECYP2D6CYP2C19GABBR2GABBR1 | |
| Ammonia Solution, Strong SCHEMBL2341560 | 0.78 | GABBR2 (0.53) | KDM4ECYP2D6CYP2C19GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115537406-B | Ketoreductase and application thereof in preparation of (S) -1- (4-pyridyl) -1, 3-propanediol | 尚科生物医药（上海）有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-115537406-A | Ketoreductase and application thereof in preparation of (S) -1- (4-pyridyl) -1,3-propylene glycol | 尚科生物医药（上海）有限公司 | 2022-12-30 | — | — | CN | claimed |
| EP-1405917-B1 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | SALTIGO GMBH (DE) | 2013-08-14 | — | — | EP | claimed |
| EP-4658667-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024163691-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | MERCK SHARP & DOHME LLC (US) | 2024-08-08 | — | — | WO | disclosed |
| EP-2489658-A1 | 3-Heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity | Allergan, Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2474534-A1 | 3-Aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity | Allergan, Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7553970-B2 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2009-06-30 | — | — | US | disclosed |
| WO-2008011483-A2 | METHODS FOR TREATING CHRONIC PAIN USING 1- (HETERO) ARYL-1-HYDROXY 2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2004-09-16 | — | — | US | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | HPD, HAAO, GRHPR | MMP12 3414/4885MMP13 1159/4885KDM4E 2493/4885 |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | MMP12 1320/4885MMP13 4232/4885KDM4E 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.